Contents

Preface to the Series ................................................................. V
Preface to Volume XII ............................................................... VII
Contents of Volumes I – XII (Chapter Headings only) ....................... XV
Contributors ........................................................................... XIX

1  Drugs Monitored during Therapy ............................................. 1

1.1  Introduction ........................................................................... 2

William E. Evans and Michael Oellerich

1.2  Theophylline ........................................................................ 5

Michael Oellerich

1.2.1  Determination with Enzyme-multiplied Immunoassay Technique ... 7

1.2.2  Determination with Substrate-labelled Fluorescent Immunoassay ... 15

1.3  Caffeine ............................................................................... 23

Thomas Zysset and Prithipal Singh

1.4  Phenytoin ......................................................................... 33

Leonello Leone and Emilio Perucca

1.4.1  Total Phenytoin ................................................................. 37

1.4.1.1  Determination with Enzyme-multiplied Immunoassay Technique ... 37

1.4.1.2  Determination with Substrate-labelled Fluorescent Immunoassay ... 43

1.4.2  Free Phenytoin, Determination by Ultrafiltration and Enzyme-multiplied Immunoassay ... 50

1.5  Primidone ......................................................................... 56

Leonello Leone and Emilio Perucca

1.5.1  Determination with Enzyme-multiplied Immunoassay Technique ... 58

1.5.2  Determination with Substrate-labelled Fluorescent Immunoassay ... 63

1.6  Phenobarbital ..................................................................... 69

Leonello Leone and Emilio Perucca

1.6.1  Determination with Enzyme-multiplied Immunoassay Technique ... 70

1.6.2  Determination with Substrate-labelled Fluorescent Immunoassay ... 76
1.7 Ethosuximide .................................................. 82
Leonello Leone and Emilio Perucca
1.7.1 Determination with Enzyme-multiplied Immunoassay Technique .... 84
1.7.2 Determination with Substrate-labelled Fluorescent Immunoassay .... 89
1.8 Carbamazepine ............................................... 95
Thomas M. Li
1.9 Valproic Acid ................................................. 103
Hans Reinauer
1.10 Digoxin, Digitoxin ......................................... 112
Gerd Kleinhammer and Hans Mattersberger
1.10.1 Determination with Enzyme-linked Immunosorbent Assay ......... 115
1.10.2 Determination with Enzyme-multiplied Immunoassay Technique .... 124
1.11 Methotrexate ............................................... 134
William E. Evans and Michael L. Christensen
1.11.1 Determination with Enzyme-multiplied Immunoassay Technique .... 137
1.11.2 Determination with Enzyme-linked Immunosorbent Assay ......... 144
1.11.3 Determination with Enzyme-inhibition Assay ....................... 152
1.12 Amikacin, Gentamicin, Netilmicin, Tobramycin
Determination with Enzyme-multiplied Immunoassay Technique ....... 159
Markus Wenk
1.13 Gentamicin
Determination with Competitive Enzyme-linked Immunosorbent Assay ........................................ 172
Jim Standefer
1.14 Kanamycin A ................................................. 187
Tsunehiro Kitagawa and Kunio Fujiwara
1.15 Viomycin and Ampicillin ................................... 200
Tsunehiro Kitagawa
1.16 Disopyramide, Lidocaine, Procainamide, N-Acetylprocainamide, Quinidine ......................... 216
Clarence T. Ueda and Mary C. Haven
1.16.1 Determination with Enzyme-multiplied Immunoassay Technique .... 220
1.16.2 Determination with Substrate-labelled Fluorescent Immunoassay .... 226

1.17 Nortriptyline .................................................. 232
Vincent Marks and Graham P. Mould

1.18 Aprotinin .......................................................... 246
1.18.1 Enzyme-linked Immunosorbent Assay .......................... 246
Werner Müller-Esterl
1.18.2 Inhibition Assay ............................................. 257
Marianne Jochum

2 Drugs of Abuse and of Toxicological Relevance ............... 265
2.1 Introduction ...................................................... 266
Christopher P. Price, Peter M. Hammond, R. Stewart Campbell and Tony Atkinson

2.2 Amphetamine (and Methamphetamine) ......................... 269
Christopher P. Price and R. Stewart Campbell

2.3 Barbiturates ....................................................... 278
Christopher P. Price and R. Stewart Campbell
2.3.1 Determination in Serum with Enzyme-multiplied Immunoassay Technique ........................................... 280
2.3.2 Determination in Urine with Enzyme-multiplied Immunoassay Technique ............................................... 284

2.4 Benzodiazepines .................................................. 291
Christopher P. Price and R. Stewart Campbell
2.4.1 Determination of Diazepam in Serum with Enzyme-multiplied Immunoassay Technique ............................. 292
2.4.2 Determination of Oxazepam in Urine with Enzyme-multiplied Immunoassay Technique ............................. 297

2.5 Methadone ........................................................ 303
Christopher P. Price and R. Stewart Campbell

2.6 Methaqualone ..................................................... 310
Christopher P. Price and R. Stewart Campbell
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.7</td>
<td>Morphine and Codeine</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>317</td>
</tr>
<tr>
<td>2.8</td>
<td>Benzoylecgonine</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>325</td>
</tr>
<tr>
<td>2.9</td>
<td>Phencyclidine</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>332</td>
</tr>
<tr>
<td>2.10</td>
<td>Propoxyphene</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>339</td>
</tr>
<tr>
<td>2.11</td>
<td>Δ⁹-Tetrahydrocannabinol</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>347</td>
</tr>
<tr>
<td>2.12</td>
<td>Nortryptiline (and Amitryptiline)</td>
<td>Christopher P. Price and R. Stewart Campbell</td>
<td>355</td>
</tr>
<tr>
<td>2.13</td>
<td>Paracetamol (Acetaminophen)</td>
<td>Christopher P. Price, R. Stewart Campbell, Peter M. Hammond and Tony Atkinson</td>
<td>362</td>
</tr>
<tr>
<td>2.13.1</td>
<td>Determination with Enzyme-multiplied Immunoassay Technique</td>
<td></td>
<td>364</td>
</tr>
<tr>
<td>2.13.2</td>
<td>Determination with Aryl Acylamidase</td>
<td></td>
<td>369</td>
</tr>
<tr>
<td>2.14</td>
<td>Salicylic Acid</td>
<td>Christopher P. Price, Peter M. Hammond, S. A. Paul Chubb, R. Stewart Campbell and Tony Atkinson</td>
<td>374</td>
</tr>
<tr>
<td>2.15</td>
<td>Nicotine</td>
<td>Alberto Castro and Nobuo Monji</td>
<td>381</td>
</tr>
<tr>
<td>2.16</td>
<td>Drug Residues in Animal Blood</td>
<td>James Fleeker</td>
<td>391</td>
</tr>
<tr>
<td>3</td>
<td>Pesticides</td>
<td></td>
<td>403</td>
</tr>
<tr>
<td>3.1</td>
<td>Introduction</td>
<td>Hans Ulrich Bergmeyer</td>
<td>404</td>
</tr>
<tr>
<td>3.2</td>
<td>Organophosphorus and Carbamate Residues in Water</td>
<td></td>
<td>406</td>
</tr>
<tr>
<td>3.2.1</td>
<td>Radiometric Method</td>
<td>László Horváth</td>
<td>406</td>
</tr>
</tbody>
</table>
3.2.2 Colorimetric Method ............................................ 412
  Gyöngyi Kovács Huber

3.3 Pesticides in Plants ............................................. 418
  Anna Wędzisz

3.4 Paraoxon in Body Fluids ....................................... 426
  Kenneth W. Hunter, Jr., David E. Lenz and Alan A. Brimfield

3.5 Atrazine in Water ............................................... 438
  Sigmund J. Huber and Bertold Hock

3.6 Paraquat in Soil ................................................ 451
  Jill P. Benner and Zbigniew Niewola

Appendix ................................................................. 465

1 Symbols, Quantities, Units and Constants ....................... 466
2 Abbreviations for Chemical and Biochemical Compounds ........... 469
3 Formulae ............................................................. 478
4 Absorption Coefficients of NAD(P)H ............................. 489

Index ................................................................. 491
1.18.2 Inhibition Assay

Marianne Jochum

General

The biomedical use of the low molecular-weight \( M_r = 6500 \) proteinase inhibitor aprotinin (Trasylol®), from bovine tissue cells is based on its broad inhibitory specificity. Major target enzymes are trypsin, chymotrypsin, plasmin, tissue kallikrein and plasma kallikrein. Hence, administration of aprotinin to patients is recommended as part of the therapeutic regimen of various diseases, in particular in shock syndromes, hyperfibrinolysis or acute pancreatitis (for review cf. [1]). Serum or plasma levels of aprotinin obtained after intravenous injection decline rather rapidly due to distribution of the inhibitor in the extracellular fluid and subsequent accumulation, primarily in the kidney [2, 3]. Therefore, one major prerequisite for the optimization of the proteinase inhibitor therapy is the quantitative assessment of the inhibitor levels in patients’ plasma or other body fluids.

Application of method: in biochemistry, clinical chemistry and pharmacology.

Substance properties relevant in analysis: aprotinin can be exposed to solutions with extreme pH values [1]. Hence, acid treatment of aprotinin-containing plasma samples allows a total recovery and thereby a specific measurement of aprotinin as the only tissue kallikrein inhibitor present in these specimens.

Methods of determination: so far, aprotinin has been measured in biological samples by the trypsin inhibition assay [1, 4] or by immunological methods [5, 6]. However, these assays are inappropriate for monitoring inhibitor levels in routine clinical diagnosis because of the limited specificity of the enzyme inhibition assay and the prolonged incubation (>40 h) necessary in the immunoassays. The enzymatic determination described here circumvents these difficulties and therefore can conveniently be used as a specific and rapid bedside control of high-dosage proteinase-inhibitor therapy [7].

An enzyme-linked immunosorbent assay was developed only recently ([8], cf. chapter 1.18.1) which provides a versatile means of measuring very precisely and relatively rapidly (4 h) large numbers of aprotinin-containing samples from plasma and other body fluids. This assay is suitable for special purposes, e.g. for monitoring lower dose inhibitor therapy in retrospective studies.

International reference method and standards: not yet available.
Assay

Method Design

Principle

(a) Aprotinin + tissue kallikrein (excess) → \[ \text{aprotinin-tissue kallikrein} + \text{tissue kallikrein (remaining)} \]

(b) \[ \text{D-Val-Leu-Arg-4-NA} + \text{H}_2\text{O} \xrightarrow{\text{tissue kallikrein (remaining)}} \]

\[ \text{D-Val-Leu-ArgOH} + 4\text{-nitroaniline} \]

After incubation of acid-treated plasma with tissue kallikrein (EC 3.4.21.35) in excess, the remaining amount of the enzyme is determined by its amidolytic activity on the substrate D-Val-Leu-Arg-4-NA (S-2266). The initial rate at which 4-nitroaniline is released is measured photometrically at 405 nm.

The reaction rate decreases linearly with increasing concentration of aprotinin in the range of 20000 – 80000 KIU* per litre plasma. The concentration of aprotinin is calculated from a calibration curve prepared by diluting normal plasma to which aprotinin (2 × 10^5 KIU/l) has been added before acid treatment.

Optimized conditions for measurement: an enzyme activity of 1 KU** is used in the assay mixture; taking \( K_m \) into account, the substrate concentration of 0.15 mmol/l ensures minimal influence of substrate depletion. Pre-incubation of acid-treated aprotinin-containing samples with the enzyme for 5 min at pH 8.2 is sufficient to achieve complete complex formation. Since the kallikrein activity towards the chromogenic peptide substrate is increased by the addition of plasma, all dilutions of aprotinin-containing plasma samples have to be performed with aprotinin-free plasma instead of buffer: in this way, the same amount of plasma (e.g. 25 µl) is always added to the assay system.

Temperature conversion factors: the assay should be performed at 37°C. Conversion factors for other temperatures have not yet been determined.

Equipment

Spectrophotometer or spectral-line photometer capable of exact measurement at 405 nm, provided with a thermostatted cuvette holder; water-bath, centrifuge (Eppendorf 5412); recorder or stopwatch; semi-microcuvettes.

---

* KIU biological kallikrein inhibitor unit (cf. [1]).
** KU biological kallikrein unit (cf. [1]).
Reagents and Solutions

Purity of reagents: all chemicals should be of the highest analytical grade commercially available.

Preparation of solutions (for about 280 determinations): all solutions in re-purified water (cf. Vol. II, chapter 2.1.3.2).

1. Buffer (Tris, 0.2 mol/l, pH 8.2):
   
   dissolve 24.2 g tris(hydroxymethyl)aminomethane in 800 ml water, adjust to pH 8.2 with HCl, 1 mol/l (approximately 100 ml), and dilute to 1000 ml with water (25°C).

2. Substrate solution (D-Val-Leu-Arg-4-NA, 1.5 mmol/l):
   
   dissolve 25 mg S-2266 (from AB Kabi Diagnostica, Stockholm, Sweden) in 28.8 ml water.

3. Porcine pancreatic kallikrein solution* (10⁶ KU/l):
   
   dissolve the lyophilized enzyme with sterile physiological saline (adjusted to pH 7.5 with triethanolamine) to a stock solution of 10⁶ KU/ml. Prepare further dilutions for the assay (5 x 10⁴ KU/l $\Leftrightarrow$ 1 KU/20 µl) freshly each day.

4. Normal human plasma:
   
   take blood specimens from veins of at least ten healthy blood donors (9 vol blood and 1 vol sodium citrate solution, 0.1 mol/l). Prepare plasma by centrifugation at 2000 g for 20 min at 4°C. Mix equal amounts of plasma from each donor and dispense in small volumes. Treat with perchloric acid (6) as described for samples under Collection and treatment of specimens.

5. Aprotinin standard solutions:
   
   use ampoules with 2 x 10⁵ KIU/10 ml, pH 5, from Bayer AG, Leverkusen; add 10 µl (200 KIU) to 1 ml normal plasma (4) for preparation of the calibration curve. Dilute this stock solution (10⁵ KIU/l) with aprotinin-free normal plasma (4) according to the following scheme:

* Research product from Bayer AG, Wuppertal-Elberfeld.
260 | Drugs Monitored during Therapy

<table>
<thead>
<tr>
<th>Stock solution (10^5 KIU/l) µl</th>
<th>Normal plasma µl</th>
<th>KIU per assay</th>
<th>KIU (× 10^3) per l untreated plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>190</td>
<td>0.125</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>90</td>
<td>0.25</td>
<td>20</td>
</tr>
<tr>
<td>20</td>
<td>80</td>
<td>0.50</td>
<td>40</td>
</tr>
<tr>
<td>30</td>
<td>70</td>
<td>0.75</td>
<td>60</td>
</tr>
<tr>
<td>40</td>
<td>60</td>
<td>1.00</td>
<td>80</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>1.25</td>
<td>100</td>
</tr>
</tbody>
</table>

6. Perchloric acid solution (PCA, 30 g/l):

dilute 8.57 ml 70% (w/v) PCA with 191.43 ml water.

7. Potassium carbonate solution (K\textsubscript{2}CO\textsubscript{3}, 5 mol/l):

dissolve 6.91 g K\textsubscript{2}CO\textsubscript{3} in 8 ml water and dilute to 10 ml with water.

**Stability of solutions:** store all solutions at 2°C to 8°C. Solutions (1) and (7) are stable for two months if not contaminated with micro-organisms. Solution (2) is stable for six months if prepared with sterile water and kept in the dark. Solution (3) is stable for at least two weeks. If not contaminated, solutions (5) and (6) are stable indefinitely. Normal plasma (4) is stable for at least 3–4 months at −20°C or more than 6 months at −70°C. Commercially available lyophilized normal plasma may also be used.

**Procedure**

**Collection and treatment of specimens:** take blood specimens from the vein without stasis (9 vol blood + 1 vol sodium citrate solution, 0.1 mol/l). Prepare plasma by centrifugation at 2000 g for 20 min at 4°C.

Acid treatment of plasma samples: incubate plasma (e.g. 0.5 ml) for 10 min at 25°C with an equal volume of PCA solution (6). Centrifuge for 10 min at 10000 g, neutralize ca. 0.980 ml supernatant with ca. 20 µl K\textsubscript{2}CO\textsubscript{3} solution (7), keep at 4°C to 8°C for further 30 min and thereafter centrifuge again for 10 min. Freeze the resulting supernatant at −20°C or below.

**Stability of aprotinin in the sample:** aprotinin in plasma is stable at room temperature at least for 1 day or at 4°C for 2 days. Aprotinin solutions of pH < 4 should be used within a few hours. Neutralized aprotinin-containing plasma samples can be stored for 1 month at −20°C or for 6 months at −70°C. Repeated freezing and thawing (n = 10) has no influence on the inhibitory activity of aprotinin in plasma.
Details for measurements in other samples: the same procedure may be used for measurements in serum and other specimens.

Assay conditions: wavelength Hg 405 nm; light path 10 mm; final volume 1 ml; temperature 37 °C (thermostatted cuvette holder). Measure against air. Before starting the assay, adjust temperature of solutions to 37 °C.

Establish a calibration curve using aprotinin solution (5) instead of sample.

Measurement

<table>
<thead>
<tr>
<th>Pipette successively into the cuvette:</th>
<th>blank</th>
<th>sample</th>
<th>concentration in assay mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris buffer (1)</td>
<td>0.855 ml</td>
<td>0.855 ml</td>
<td>Tris 171 mmol/l</td>
</tr>
<tr>
<td>normal plasma (4)</td>
<td>0.025 ml</td>
<td>–</td>
<td>aprotinin up to 1250 KIU/l</td>
</tr>
<tr>
<td>sample or standard (5)</td>
<td>–</td>
<td>0.025 ml</td>
<td>kallikrein 1000 KU/l</td>
</tr>
<tr>
<td>kallikrein solution (3)</td>
<td>0.020 ml</td>
<td>0.020 ml</td>
<td>D-Val-Leu-Arg-4-NA 0.15 mmol/l</td>
</tr>
</tbody>
</table>

mix thoroughly with a plastic spatula, wait for 5 min,

<table>
<thead>
<tr>
<th>substrate solution (2)</th>
<th>0.100 ml</th>
<th>0.100 ml</th>
</tr>
</thead>
</table>

mix and read absorbance each min or monitor the reaction on a recorder over a period of 5 min.

If the amount of aprotinin in the sample exceeds 1.0 KIU per assay, plasma samples must be diluted with aprotinin-free, acid-treated normal plasma (4).

Fig. 1. Typical calibration curve for the assay of aprotinin in plasma.
Calibration curve: calculate \((\Delta A/\Delta t)_{\text{sample}}\) in percent of \((\Delta A/\Delta t)_{\text{blank}}\). Plot the percent of free enzyme activities of the standards against their activity concentrations of aprotinin (Fig. 1).

Calculation: the inhibitory activity of aprotinin in the sample (patients' plasma) is taken from the calibration curve.

Validation of Method

Precision, accuracy, detection limit and sensitivity: the within-run imprecision for aprotinin, \(4 \times 10^4\) KIU/l was 1.8 – 10.8% in 8 series; the between-series imprecision \((n = 8)\) was 4.4%. The recovery for \(2 \times 10^4\) to \(8 \times 10^4\) KIU/l (working range) was 90 – 125%. Data on accuracy are not available since standard reference material is not established yet.

The detection limit is 0.125 KIU per assay, i.e. \(10^4\) KIU/l of untreated plasma. Sensitivity is found to be \(\Delta A/\Delta t = 0.002/\text{min}\) at 405 nm (Eppendorf photometer). the mean 1.23-fold increase caused by pooled plasma. With an individual increase in

Sources of error: since kallikrein activity is increased 1.23-fold \((n = 90; \text{RSD} = 7.2%)\) by addition of acid-treated normal plasma, all dilutions of aprotinin-containing plasma samples must be made with aprotinin-free, acid-treated plasma. Plasma samples without acid treatment cannot be used because of a rather high and irregular stimulation of the kallikrein activity in the assay system. The same holds true for serum. Dilution of aprotinin-containing plasma samples with buffer or isotonic saline solution instead of plasma yields too low inhibitor concentrations.

Occasionally, aprotinin-free plasma samples from a single individual may stimulate kallikrein activity to a lesser (up to 1.1-fold) or greater (up to 1.5-fold) extent than kallikrein activity lower than 1.15-fold or higher than 1.3-fold, the calibration curve and dilutions of aprotinin-containing plasma samples should be performed with the individual patient’s plasma (pre-aprotinin infusion sample) instead of pooled plasma.

Addition of \(\text{NaN}_3\) to aprotinin-containing plasma as a preservative before acid treatment partly destroys the inhibitor activity during the subsequent procedure.

Specificity: under the given conditions the substrate S-2266 is split specifically by the tissue kallikrein used in the assay.

Therapeutic ranges: continuous i.v. infusion of \(250000\) KIU/h in polytraumatized patients resulted in a mean plasma concentration of \(4.5 \times 10^4\) KIU/l [7].
References


